Intravitreal Dexamethasone Implant for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion




To evaluate the efficacy and safety of dexamethasone intravitreal implant in thetreatment of macular edema owing to branch retinal vein occlusion.


The results of dexamethasone intravitreal implant injections in 47 patients (47 eyes) with macular edema due to non-ischemic branch retinal vein occlusion were retrospectively analyzed. The age of patients ranged from 38 to 77 years (27 male, 20 female). The duration of the disease at the time of dexamethasone implant intravitreal injection ranged from 4 days to 8 months. Best corrected visual acuity, intraocular pressure were measured and optical cohorence tomography was performed at four month follow-up.


35 eyes (74,4%) were phakic and 12 eyes (24,6%) were pseudophakic. Average number of injections per patient was 1.3. Baseline visual acuity was 0.66 logMAR and improved to 0.52 logMAR at four month followup. Average central retinal thickness was 457.2 microns at baseline and decreased to 350.7 microns at fourmonths. 35 patients were phakic at start of treatment, and only one of the patients needed cataract extraction to date. 5 patients (10,6%) required topical treatment for raised intraocular pressure.


Dexamethasone intravitreal implant resulted in anatomical and functional improvement in patients with macular edema secondary to branch retinal vein occlusion and presented a good safety profile. The intraocular pressure increases were usually transient and controlled with medication or observation. Treated patients not only had improvement in macula thickness but also had improvements in final best-corrected visual acuity post treatment.


Mustafa Elcioglu
Istanbul, Turkey
Email :
Cell Phone: +905322361551
Work Phone: +905322361551